Clinical Trials Directory

Trials / Completed

CompletedNCT02534389

Fish Oil Supplement in Rectal Cancer

Fish Oil Supplement Combined With Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
100 (actual)
Sponsor
AC Camargo Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Neoadjuvant treatment with radiotherapy (RDT) and chemotherapy (CT) are the treatment of choice for rectal adenocarcinomas in stages II and III. This results currently in pathologic complete response in 10% to 30% of cases. The immune and inflammatory response is altered in these individuals and is directly related to response to therapy. Both the disease and the treatment of colorectal cancer have an impact on quality of life and nutritional status. In studies with cells and animal models the incorporation of fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic (DHA) - derived from fish oil - has been shown to interfere in the process of inflammation, cell signaling and gene transcription enhancing the response to treatment. Are reported ability to restore the apoptosis of tumor cells, sensitization of tumor cells to chemotherapy, production of less pro-inflammatory cytokines and the preservation of normal energy and protein metabolism. The aim of this study is to verify if the daily consumption of 2.4 g EPA + DHA for adults in neoadjuvant therapy can promote changes on inflammatory and immunological markers of host response to tumor and if this response is altered by nutritional status. It is expected that supplementation can reflect in control of inflammatory and immune response in favor of tumor cell death contributes to pathological complete response and that it happens with preservation of nutritional status. Subjects will be randomized as to supplementation. All will be assessed in four moments during neoadjuvant therapy and immediate postoperative. Results will be presented by comparing the intervention group and control group at each moment.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTomega-3 fish oil2,4g of EPA + DHA

Timeline

Start date
2015-01-01
Primary completion
2016-07-01
Completion
2017-02-01
First posted
2015-08-27
Last updated
2017-02-09

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT02534389. Inclusion in this directory is not an endorsement.